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ABSTRACT  
The diagnosis of tuberculosis (TB) in Human Immunodeficiency Virus (HIV) infected 
individuals is a challenge due to atypical presentations including negative sputum smear 
and culture results, which renders traditional microbiological tests inadequate in this 
population. Immune based assays are an attractive alternative, but current commercial 
blood interferon gamma (IFNγ ) release assays have limited utility in areas of high 
Mycobacterium tuberculosis (M. tuberculosis) prevalence. Immune responses in the lung 
differ from those in peripheral blood, hence a better understanding of lung compartment-
specific immune response to TB may assist in developing new diagnostic assays.We 
evaluated the IFNγ production from induced sputum (ISp) and blood samples of 31 HIV 
positive, smear-negative TB suspects who were being investigated for active TB. We 
analysed the IFNγ responses of total lymphocytes in ISp samples; and total, CD4+ T 
lymphocytes and memory CD27- CD4+ T lymphocytes in blood. IFNγ was quantitated 
after stimulation with two M. tuberculosis antigens, PPD (purified peptide derivative) and 
ESAT6 (early secretory antigen 6). Eleven sputum samples were excluded due to poor 
sample quality.We observed that IFNγ secretion from total lymphocytes in sputum was, 
significantly higher than blood after stimulation with either ESAT6 (0.64% vs 0.10%, p = 
0.03) or PPD (2.04% vs 0.21%, p = 006), and the PPD specific IFNγ secreting 
lymphocytes in sputum could be used to differentiate between the M. tuberculosis negative 
and positive groups. None of the lymphocyte populations analysed in blood differentiated 
these two M. tuberculosis groups.  The counterintuitive finding is that, median PPD 
specific IFNγ secreting lymphocytes in sputum were significantly lower (p = 0.04) in the 
M. tuberculosis positive (0.23%) cohort when compared to the M. tuberculosis negative 
group (2.04%). The sensitivity and specificity of this finding to discriminate active and 
latent TB at a diagnostic threshold of 1.25% PPD-specific IFNγ secreting total sputum 
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lymphocytes is 78% and 70% respectively. The routine diagnostic utility of measuring T 
lymphocyte immune responses in sputum by flow cytometry however is not practical due 
to limitations imposed by the required cellular content and viability, as well as the need to 
process these samples within two hours of collection. These results however, are valuable 
and add insight into the lung compartment specific immune response to M. tuberculosis 
antigens. 
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CHAPTER ONE 
1.0 Background 
1.1 Introduction 
M. tuberculosis causes about two to three million deaths annually and globally has the 
highest mortality for any single infectious agent (1). South Africa is classified as a high TB 
and Human Immunodeficiency virus (HIV) burden country. According to the World 
Health Organisation TB database (54) the South African TB prevalence in 2010 was 400 
000, with a rate of 795 per 100 000 population. The prevalence of TB has doubled over the 
last decade. The increased burden of the disease in South Africa has been attributed to 
overcrowding, poor ventilation and malnutrition but currently, as shown in Table 1.1, is 
fuelled by the prevailing HIV epidemic.This increase in prevalence  is likely due to an  
increased risk of  infection, reactivation of latent TB or the rapid progression to active TB 
in M. tuberculosis and HIV co-infected individuals (2). 
 
Table 1.1 WHO 2010 TB data for South Africa (54) shows the high percentage of HIV 
infection in patients with TB. 
TB patients with known HIV status 213 006 
% of TB patients with known HIV status 54 
TB patients that are HIV-positiv 128 457 
% of tested TB patients that are HIV-
positive  
60 
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TB remains one of the great killers despite the availability of adequate chemotherapeutic 
agents and a vaccine. The lack of diagnostic assays with high sensitivity and specificity is 
partly responsible for the inadequate control of the disease (3). Additionally, culture of the 
organism which is the gold standard for diagnosing TB requires 7- 42 days to detect 
bacterial growth (4), resulting in delayed diagnosis and further spread of TB. Furthermore, 
the diagnosis of M. tuberculosis infection in HIV co-infected individuals is challenging as 
patients present atypically, often having less cavitatory disease and more extra-pulmonary 
disease. Routine diagnostic approaches such as sputum smears for acid fast bacilli (AFB) 
and typical clinical and radiological features are therefore not appropriate in this group (5).  
Importantly these undiagnosed patients  who often are AFB sputum negative (6) are 
capable of transmitting mycobacteria despite  its lack of detection in the sputum (7) and 
therefore serve as a point source for further spread of the disease (8). 
 
 In 2005, the World Health Organisation declared the increasing global epidemic of TB an 
emergency requiring that urgent and extraordinary actions be undertaken. This increased 
the awareness that new prevention, diagnostic and treatment strategies were needed to 
control this epidemic in the era of HIV. A quick and accurate diagnostic tool for M. 
tuberculosis could save a quarter of the approximately two million lives lost to TB each 
year (3). For the reasons stated above, a diagnostic test for active TB that can be applicable 
in a high TB burden area and that does not rely on the direct detection of AFB in sputa is 
urgently required in HIV and M. tuberculosis co-infected individuals. Measurement of M. 
tuberculosis specific immune responses is a good candidate for this diagnostic approach. 
Elucidation of the immune response to M. tubeculosis lead to the discovery that M. 
tuberculosis specific IFNγ response could be used as a biomarker of the disease. The 
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immune response to M. tuberculosis, as well as the principle and limitations of 
commercially available IFNγ based assays are discussed in detail below.  
Flow cytometry offers a novel approach to measure M. tuberculosis specific IFNγ 
secretion. A previous publication (9) suggested  that the use of a simple flow cytometric 
assay performed on ISp may differentiate active from latent TB. This promising finding 
was, however, from an area of low TB prevalence. We chose to apply this methodology to 
a group of HIV infected patients in a high TB prevalence setting. The aims of this study 
were to:  elucidate the pulmonary-specific T lymphocyte immune responses to M. 
tuberculosis by comparing the IFNγ responses in blood and sputum; and to evaluate the 
potential application of this assay to diagnose active TB in this group of patients who are 
most in need of improved diagnostics, that is, individuals with two negative smears for 
acid fast bacilli but in whom clinical suspicion of active TB persists. 
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1.2.0 TB diagnostic assays 
1.2.1 Historical background 
The high burden of TB in South Africa can be likened to that of England a century ago. 
England’s triumph in controlling the disease can be attributed to an improvement in socio-
economic factors but also to the active TB research that occurred during that period. At the 
end of the nineteenth century, a microbiologist named Robert Koch identified M. 
tuberculosis as the causative agent in TB. A few years later, he attempted to develop a 
therapy using a sterile filtrate from in vitro cultures, but this induced a very strong 
inflammatory response that caused a severe necrotic reaction, called Koch’s phenomenon, 
in patients with active TB. This lead to the discovery of the tuberculin skin test (TST) 
which is in use to date, almost 100 years later (10), and despite its numerous limitations. 
This highlights the lack of research interest in this field over the last century. The recent 
establishment of the global Stop TB Strategy however, has created renewed awareness and 
interest in the development of new M. tuberculosis diagnostic assays (11).   
  
1.2.2 Current active TB diagnostic assays and their limitations in HIV and TB co-
infection 
The diagnosis of active TB is currently based on clinical signs and symptoms, sputum 
smear microscopy results, x-ray changes and culture. More recently molecular 
amplification techniques such as the Polymerase Chain Reaction (PCR) with improved 
extraction methodologies to improve sensitivity have become available. Despite further 
recent advances to these technologies, their sensitivity and specificity largely remains 
suboptimal in the setting of HIV, (Table 1.2) (5) (4). The recent introduction of the Xpert 
MTB/RIF (GeneXpert, Cepheid), which employs a molecular amplification method,  has 
created excitement in South Africa, as even with an HIV prevalence of 60-80% in TB 
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suspects, the sensitivity of GeneXpert for smear positive patients has been reported as 
greater than 90% (correctly detected 551 of 561 patients) and for sputum smear negative 
patients as 72% (correctly detected 124 of 171 patients) (12). However, while this 
represents an improvement over existing methods, this does not solve all the diagnostic 
dilemmas in culture negative or even GeneXpert negative, HIV infected patients.   
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Table 1.2 Impact of HIV on TB Diagnosis.  
TECHNIQUE and its 
LIMITATIONS 
ADVANCES  IMPACT of HIV 
Clinical presentation and 
radiology: not specific as 
bacterial pneumonia and 
non-infective diseases can 
produce similar features. 
- Atypical presentation : Lack 
of a persistent cough or 
night sweats; more extra-
pulmonary disease; less 
cavitatory disease on chest 
x-ray (CXR) 
Smear Microscopy: 
requires skill, labour 
intensive and direct 
detection of organism 
needed, hence sputum 
cannot be used to diagnose 
extra-pulmonary disease. 
Use of fluorescent 
microscopy to increase 
sensitivity 
Paucibacillary and extra-
pulmonary disease more 
common. 
 
Culture: despite being the 
gold standard, often leads to 
delay in diagnosis owing to 
prolonged time required for 
growth detection. 
Liquid culture systems that 
are more sensitive and 
decrease growth detection 
time to 7 days. 
Paucibacillary disease and 
higher contamination rates, 
which lead to further delays 
in diagnosis and invalid 
results. 
PCR : M.tuberculosis needs 
to be present in sample and 
extra-pulmonary infection 
cannot be detected from 
sputum samples. 
Line probe (LPA) and real 
time assays that 
simultaneously detect 
infection with M. 
tuberculosis and regions of 
drug resistance. Examples 
are:  Genotype MTBDR, 
Hain Lifesciences, 
Germany and  Xpert 
MTB/RIF (GeneXpert, 
Cepheid), respectively. 
The GeneXpert has a 
sensitivity of almost 100% 
in smear positive samples 
but is decreased (66-72%) 
in smear negative cases, 
which are more prevalent in 
HIV and TB co-infection.   
 Adapted from references (3) and (27). 
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1.2.3 Diagnosis of latent TB infection and the IGRA 
 Latent tuberculosis infection (LTBI) is defined as the absence of clinical signs or 
symptoms of active TB in an individual who has a history of exposure to M. tuberculosis 
and a corresponding positive TST (13). It remains critical to differentiate active from latent 
TB, since a diagnosis of TB commits an individual to a 6 month multi-drug anti-
tuberculosis regimen. Furthermore this places the patient at risk of unwarranted toxicity 
and drug resistance (14). The commercial assays available to diagnose latent TB include 
the TST and IGRAs. 
 
The TST, which is an in vivo test, involves the injection of a Tuberculin antigen 
intradermally and the presence of a wheal and its diameter is read 48 – 72 hours after 
injection. The TST has been the standard diagnostic test for LTBI, despite having a lower 
sensitivity in HIV positive patients and cross-reacting with components of the Bacille 
Calmette-Guerin (BCG) vaccine, as well as with Mycobacteria other than tuberculosis 
(MOTTs) (25). Blood based immune-mediated assays that detect IFNγ production have 
recently been developed to detect M. tuberculosis infection. These make use of the Region 
of difference (RD1) antigens found almost exclusively in M. tuberculosis but not in other 
mycobacteria or the BCG vaccine (15). This eliminates the cross-reactivity from BCG 
vaccination and most MOTTs, and is an improvement over the TST assay. The other 
advantages of IGRA assays over the TST is that a single patient visit is required; the 
turnaround time is halved; there are no boosting effects on the patients immune system;  
the results are more reproducible and objective, and this assay is run in the presence of 
controls (16).  
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 The blood based immune ex-vivo assays include the enzyme-linked immunosorbent assay 
known as  Quantiferon-TB Gold in-Tube (Pro-Gen Diagnostics, South Africa), which is a 
whole blood tube method and the T.Spot TB test (Oxford Immunotech, Calicom trading, 
South Africa), a histochemical blot method. The RD1 antigens used include early secretory 
antigen 6 (ESAT6) and culture filtrate protein 10 (CFP 10). Despite their increased 
specificity, their value in advanced HIV infection remains controversial, requiring further 
evaluation studies. Studies have demonstrated that the  immunological response produced 
by these antigens are weak in HIV positive individuals who progress to the Acquired 
Immunodeficiency Syndrome (AIDS) (17) . 
 
Most studies show that although the commercial IGRAs are unable to differentiate between 
active and latent TB, they are capable of differentiating individuals exposed to TB from 
those that have never been exposed. Hence, they have gained favour in settings of low TB 
prevalence for detecting patients with latent TB who can be treated with anti-tuberculosis 
eradication therapy in these areas. However, use of these assays in routine TB diagnosis in 
highly TB endemic areas remains unlikely (18). In South Africa, Isoniazid (INH), an anti-
tuberculosis drug is recommended as monotherapy to prevent reactivation of latent M. 
tuberculosis infection in some immunosuppressed groups, including those that are HIV 
infected. Multi-drug eradication therapy is not recommended for latent TB infection in 
high burden countries. Hence we require diagnostic tools that can differentiate active from 
latent TB, not merely exposure to M. tuberculosis from non-exposure. Thus, a better 
understanding of the immune responses to M. tuberculosis is required to develop an 
immune based test to distinguish active from latent infection.  
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1.3 Transmission and clinical spectrum of TB in HIVuninfected and infected 
individuals 
The discovery of new immunodiagnostic tools such as the interferon gamma release assays 
(IGRA) have improved the understanding of the immuno-pathogenesis of human TB. New 
evidence suggests that fifty percent of HIV uninfected individuals exposed to M. 
tuberculosis do not develop positive immuno-diagnostic tests, meaning that the adaptive 
immune system was not activated as these tests measure antigen specific memory 
responses (19). This implies that the innate immune system of these individuals is capable 
of sterilizing immunity, that is the complete eradication of the bacteria (20). Of the 
remaining fifty percent, that is patients with latent TB as evidenced by positive 
immunodiagnostic tests, only five percent progress to active disease (19). 
 
The transmission of TB in HIV infected individuals is similar to that in HIV negative cases 
but the progression of the disease is altered, which results in an increase in morbidity and  
mortality in co-infected individuals (2). HIV increases susceptibility to M. tuberculosis 
infection, reactivation and re-infection as well as accelerates the progression from latent to 
active disease (2). The spread of M. tuberculosis occurs when mycobacteria are aerosolised 
during coughing and then inhaled by close contacts. The mycobacteria may be contained 
and therefore remain dormant or latent within macrophages. HIV destroys the cells integral 
to the control of M. tuberculosis, namely the CD4+ T lymphocytes. When the immune 
control is disrupted, as is in the case of HIV,  reactivation of TB occurs (21). M. 
tuberculosis and HIV also act synergistically to compound the insult on the host’s immune 
system (22) as evidenced by the presence of poorly formed granulomas in co-infected 
individuals. This immune insult results in an increase in mortality. HIV positive patients 
who commence anti-retroviral therapy are also at risk of developing TB associated immune 
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reconstitution inflammatory syndrome (IRIS), which is an over-exuberant immunological 
response to the mycobacterium with deleterious consequences (4) (23).  
 
1.4 Innate and adaptive immunological responses to M.tuberculosis  
M. tuberculosis is an aerobic obligatory intracellular pathogen which enters the body via 
the respiratory route and has a predilection for the lung due to its rich oxygen supply (19).  
 
The innate mechanisms initiated to control the bacilli include plasma lysozymes, lysis by 
natural killer cells (lysis of pathogen directly or infected phagocytes) and phagocytosis. 
The CD1d restricted Natural Killer T (NKT) cells that are capable of recognizing lipid 
antigen also contribute to the protection against M. Tuberculosis (24). The M. tuberculosis  
bacteria bind to complement receptors (CR1, CR2, CR3 and CR4), mannose receptors 
(MR), Toll-like receptors (TLR2 and TLR4) and other cell surface receptors (CD14 
receptor, surfactant protein receptors) on monocytes, macrophages and dendritic cells (25). 
The bacilli may be phagocytosed by these cells resulting in phagosome-lysosome fusion, 
the release of acidic hydrolases and degradation of the bacilli. Alternate mechanisms of 
phagocyte degradation of   the engulfed bacteria include the generation of reactive oxygen 
intermediates (hydrogen peroxide), reactive nitrogen intermediates (nitric oxide), 
production of cytokines including Tumour Necrosis Factor alpha (TNFα) and IFNγ,  and 
programmed cell death (FAS-ligand mediated or TNFα induced apoptosis) (25). 
 
The role of antibodies in protection against mycobacterial infections remains controversial. 
While antibodies do form against M. tuberculosis, they do not lead to the clearance of the 
organism or immunity to re-infection. Previous explanations for the failure of antibodies to 
protect against M. tuberculosis have been based on the T helper 1/T helper 2 (Th) 
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paradigm that Th1 cells, orchestrating cellular immunity are important in protecting the 
body against intracellular pathogens while Th2 responses, with resultant antibody 
responses, protect against extra-cellular pathogens. The modern view however is that  a 
mixed response rather than a specific Th1 or Th2  response is required to protect  from 
either an intracellular or extracellular pathogen (26).  More recent studies have therefore 
further explored the role of antibodies and one such study has shown that mice that are 
unable to produce antibodies have a three to eight-fold increase in viable bacilli compared 
to normal controls (27). B-cell deficient mice also show decreased production of the 
cytokines, IFNγ and TNFα, which are central to TB control (28). Human vaccine studies 
also support the role of antibodies in protecting against severe mycobacterial infection, and 
the mechanism of action of these antibodies is most likely opsonisation which leads to 
increased phagocytosis of the organism and antigen presentation (26).  
 
The cell-mediated immune response, involving T lymphocytes is recognised as the 
classical protective response in M. tuberculosis infection. Both CD4+ and CD8+ T 
lymphocytes are important in mediating this response (29).  HIV co-infection provides 
compelling evidence for the role of CD4+ T lymphocytes in protection against M. 
tuberculosis disease. The primary effector function of CD4+ T lymphocytes is IFNγ 
production (30). The role of CD8+ T lymphocytes has been controversial, but recent work 
shows that these cells protect the host by virtue of their cytotoxic activity and production 
of IFNγ; but that the cytotoxic activity requires the help of CD4+ T lymphocytes (31). The 
CD4+ T lymphocytes however are the predominant producers of IFNγ (32). IFNγ is the 
major activator of macrophages, enhances antigen presentation and recruitment of CD4+ 
and CD8+ T lymphocytes to the site of mycobacterial infection (25). 
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1.5 Measurement of immune responses as diagnostic tools for TB  
The advantage of measuring various immune responses is that the organism does not have 
to be present in the sample, that is, it is an indirect measure of infection. Hence, it can be 
used to diagnose smear or culture negative disease as well as aid in the diagnosis of extra-
pulmonary infection (9). Researchers have reviewed the possibility of using absolute 
numbers of lymphocytes, granulocytes and natural killer T cells as tools to diagnose active 
TB (33). Quantitation of antibody responses is a simple immunodiagnostic method, but as 
discussed earlier, antibodies have largely been disregarded as diagnostic tools for active 
TB. Current research is focused on identifying antibodies to immunodominant antigens 
that could be used to diagnose individuals with active TB (34). The measurement of cell-
mediated immune responses is widely used, and two assay platforms are currently 
available to measure M. tuberculosis specific IFNγ responses.  
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1.6.0 IFNγ response in the diagnosis of active TB using flow cytometry and ISp  
1.6.1 The advantage of using pulmonary samples 
It has recently become apparent that immune responses are not uniform throughout the 
body, but may differ at different sites, such as blood, gastrointestinal tract, genitourinary 
tract, lung etc (35). The lung immune response is the major line of defense against M. 
tuberculosis even in extra-pulmonary or disseminated infection, as in most cases the lung 
is the portal of entry of the bacilli (9). For respiratory infections therefore, assessment of 
lung immune responses may be more relevant for response to infection than blood immune 
responses.  
 
 Broncho-alveolar lavage (BAL) fluid has been shown to be more sensitive for cytokine 
based assays than blood since cytokine production in response to M. tuberculosis antigens 
is ten times greater in BAL fluid than blood (36). This may relate to the fact that the lung is 
the primary site of infection or that two percent of the body’s lymphocytes reside in the 
blood and approximately ten percent are located in the lung (36).  
 
BCG vaccinated individuals show cross reactivity in the blood but not BAL, when these 
samples are stimulated with PPD, which is known to share epitopes with BCG. Pulmonary 
samples may therefore have an additional advantage over peripheral blood in areas where 
BCG vaccination is practiced (9, 36). The other advantage of using respiratory-based 
specimens, is that, these samples may simultaneously be utilised for microbiological 
detection (9). 
 
BAL is the sample retrieved after bronchoscopic infusion of saline into the distal broncho-
alveolar tree. Obtaining lung fluid this way is invasive, requires a skilled pulmonologist, 
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expensive equipment and the patient requires anaesthesia (37). ISp, in contrast to BAL, is 
less invasive and does not require anaesthesia or expensive equipment. ISp refers to the 
lung fluid expectorated after a patient is nebulised with hypertonic saline for approximately 
twenty minutes. Sputum is mainly expectorated without assistance, hence requires less 
skill to perform (8). Many studies have revealed that ISp produces a similar M. 
tuberculosis microbiological yield to BAL (38). A recent paper (39) comparing  ISp and 
BAL for the diagnosis of sarcoidosis  found good T-lymphocyte correlation between the 
two sampling procedures.  
 
1.6.2 The use of IFNγ measurement to detect active disease 
Respiratory based samples produce superior cytokine results when compared to blood, 
function as a distinct immunological compartment, and additionally can be used to 
differentiate between active and latent TB. Recent work investigating the use of the 
ELISpot on broncho-alveolar lavage fluid was found to be capable of differentiating active 
and latent TB infection by comparing the lung specific immune responses to blood in an 
HIV negative population (36). This group of investigators also used this method in an 
immunosuppressed female and were able to reproduce this finding (40).  
 
The Breen et al study (9) evaluated the role of ISp in TB diagnosis in a population 
comprising both HIV positive and negative individuals. This group used PPD as the 
stimulating mycobacterial antigen and analysed cytokine production by flow cytometry. 
This study concluded that the cytokine response in ISp was capable of diagnosing active 
TB infection in HIV positive and negative individuals and this was irrespective of the site 
of the infection. This method was capable of diagnosing pulmonary as well as extra-
pulmonary TB. Problems identified with this study were the false positive results obtained 
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in three individuals with latent infection. The false positives may be explained by their 
choice of stimulating antigen, namely PPD which is a very potent antigen (41), or may  
represent “true positives in waiting”, that is, may reflect individuals more likely to 
reactivate, who therefore require follow up (8) (42). Nonetheless, the suggested ability of 
ISp to differentiate between active and latent TB warrants further exploration, as flow 
cytometry is now available in 62 laboratories throughout South Africa for the purpose of 
CD4 T lymphocyte counting.   
 
1.6.3 Flow cytometry versus the commercially available IGRA 
The IGRAs are the first real immunological advance specific to M. tuberculosis 
diagnostics (43). These tests are superior to the TST in detecting patients who have been 
infected with M. tuberculosis (44)  and show a better correlation with progression to active 
disease in those that are latently infected (42). The limitation of this technique is that it can 
only evaluate a single cytokine, the source of the cytokine production cannot be 
determined for either the test or the control, and it has a high indeterminate rate, especially 
in the setting of HIV (15). 
 
Subsequently, the evaluation of the cytokine response to M. tuberculosis antigens has been 
found to be superior if analysed by flow cytometry, rather than using the histoblot or whole 
blood IGRAs, as flow cytometry has a higher sensitivity and specificity (14). Flow 
cytometry also allows for the simultaneous detection of the cells responsible for the 
cytokine production, in addition to the quantitation of cytokine production. It provides a 
more flexible platform in which the number of stimulants, the number of cytokines 
measured and the composition of the secreting cells can be user defined (43). The flow 
cytometry based assay is also less influenced by CD4+ T lymphocyte count as IFNγ  
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results are reported as a percentage of CD4+ T lymphocyte, and would therefore be the 
method of choice in HIV and M. tuberculosis co-infected individuals with low CD4 counts 
(15).  
 
In addition, the use of blood samples instead of compartment specific immune responses, 
suggests that active TB may be differentiated from latent/non- TB by studying the flow 
cytometric detection of IFNγ production from memory CD4+ T lymphocytes, which are 
characterized as being CD27 negative (45). Classical markers of memory phenotype such 
as CD45RO do not reproduce this finding (45) . CD27 is a member of the TNF receptor 
family where it acts as a receptor for co-stimulation. It is down- regulated when a naïve T 
cell encounters an antigen and progresses to a terminal memory cell resulting in reduced 
expression of CD27. The importance of this phenotype was elucidated in a murine-based 
study (46)  which showed that the lung IFNγ producing CD4+ T lymphocytes were CD27 
negative. The hypothesis is that these cells traffic through the blood en-route to the lung at 
the time of active M. tuberculosis infection (45).  
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1.7.0 Study objective 
The hypothesis to be tested is that lung and blood specific T lymphocyte immune 
responses, particularly M. tuberculosis specific IFNγ secretion, differs in HIV infected 
patients with active TB, compared with HIV infected patients without active TB, and that  
this may form the basis of a flow cytometric diagnostic assay for active TB.  
 
1.7.1 The aims of this study were to: 
• Optimise the flow cytometric panel for detection of IFNγ from sputum and blood. 
• Quantitate the M. tuberculosis specific IFNγ secreting total lymphocytes, CD4+ T 
lymphocytes and memory CD27- CD4+ T lymphocytes in sputum and blood. 
• Compare the percentage of M. tuberculosis specific IFNγ secreting lymphocytes 
from blood with that from sputum 
• Compare the two TB antigens, ESAT6 and PPD, in their ability to stimulate IFNγ 
secretion 
• Compare the IFNγ responses in sputum and blood with the final microbiological 
diagnosis on each patient. 
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CHAPTER TWO 
2.0 Materials and Methods 
2.1.0 Optimisation of laboratory techniques 
2.1.1 Immunofluorescence panel  
A four colour fluorescence panel was used to label the respective cells. CD3, a marker of 
the T cell receptor, was labelled with fluorescein isothiocyanate (FITC), CD4 was labelled 
with a tandem peridinin chlorophyll protein (PerCP Cy3.5), CD27 was labelled with 
allophycocyanin (APC) and IFNγ with phycoerythrin (PE).  All fluorescently labelled 
monoclonal antibodies were manufactured by Becton Dickinson, USA, including those that 
were generously provided by Dr David Murdoch, Duke University, USA. 
 
2.1.2 Titration of monoclonal antibodies 
 This procedure was used to determine the minimum amount of monoclonal antibody  
needed to achieve good discrimination between a negative and positive cell population 
while mimimising background staining. This was determined by comparing the mean 
fluorescence intensity achieved with varying concentrations of antibody. In addition, the 
signal to noise ratio (S:N) was calculated, by dividing the mean fluorescence intensity 
(MFI) of the negative and positive populations. The titration volume with the highest MFI 
and S:N ratio was selected.   
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2.1.3 Fluorescence minus one (FMO) controls 
This procedure was used to detect spill over from one fluorochrome in the flow cytometric 
panel into an incorrect channel. Fluorescence minus one (FMO) controls are carried out by 
eliminating a single fluorophore from each experiment and verifying that it was not 
detected. 
 
2.1.4 Optimisation of the flow cytometric assay using cells from ISp 
Due to the lack of established processing methods, ISp was collected from eight AFB 
negative patients being worked up for other chronic lung disorders. The aim was to 
identify an appropriate mucolytic agent, as well as the volume and time required for 
mucolysis, by determining cellular viability. The second aim was to identify the optimal 
filtration method by comparing the cellular yield obtained when either a 40um or a 100um 
filter was used. Cellular viability was assessed by counting the number of all cells, 
followed by viable cells only. Total cell counts were performed after staining with trypan 
blue (Sigma Aldrich, USA), and cells were counted using, a Neubauer Haemocytometer 
and the calculation described in Appendix 6. The erythrosin stain (Sigma Aldrich, USA) 
was used to stain the viable cells, after which the percent viability was calculated. Finally, 
the optimal gating strategy to identify lymphocytes in ISp was determined (Figure 3.2). 
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2.1.5 Optimisation of the concentration of ESAT6 and PPD 
Based on a recent review (6), two concentrations of ESAT6 and PPD (5ug/ml and 
10ug/ml) were selected to stimulate peripheral blood mononuclear cells (PBMC) from 
healthy controls. PBMC were isolated according to the procedure described in section 
2.3.2.2. The concentration that yielded the greater production of percentage IFNγ specific 
total lymphocytes was selected and IFNγ production was quantified using MFI.  
 
2.2 Patient recruitment 
This was a prospective study. Adult, HIV positive patients undergoing diagnostic work-up 
for suspected M. tuberculosis disease despite producing two negative AFB sputum smear 
samples were randomly enrolled from the TB Focal Point, Helen Joseph Hospital (HJH) or 
the Infectious Diseases ward at Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH) between June 2010 and March 2011. Patients on anti-tuberculosis chemotherapy 
for more than one week, with a history of asthma, chronic obstructive lung disease, on an 
immunosuppressant regimen or with a recent life-threatening event were excluded from the 
study. Enrollment was terminated when a similar number of patients were represented in 
the M.tuberculosis negative and positive groups. 
Ethics approval was obtained from the University of Witwatersrand, Human Research 
Ethics Committee/M090517 (Appendix 1). The study details were discussed and a written 
information sheet (Appendix 2) handed out to all participants prior to obtaining written 
informed consent (Appendix 3). A clinical data sheet (Appendix 4) was used to record all 
relevant clinical details. Study participation did not disrupt the participants’ routine 
diagnostic work-up. 
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2.3.0 Sample acquisition and processing 
Sputum induction was performed within the sputum induction facility at HJH and in the 
Infectious Diseases ward at CMJAH. These areas are equipped with ultraviolet lamps and 
an N95 mask was worn during the induction procedure. Participants were instructed to 
clear the mouth and nostrils of residual secretions prior to induction by rinsing with water. 
Twenty millilitres of 5% hypertonic saline (Sabax, Adcock Ingram, South Africa) was 
added to a nebuliser mask and delivered in six litres of oxygen per minute. The induction 
continued for fifteen to twenty minutes. Sputum was collected into a sterile container. Five 
to six millilitres of venous blood was collected into an Acid Citrate Dextrose tube. 
The intracellular cytokine staining protocol (Appendix 5) used was adapted from the 
standard operating procedure employed by the HIV Immunology laboratory, National 
Institute of Communicable Diseases, Johannesburg. The details of this protocol are 
described  below. A reagent template (Appendix 6) was used to ensure that exact reagents 
and staining master-mixes were made for each experiment. Both blood and sputum 
samples were processed simultaneously and within two hours of collection. 
 
2.3.1 Isolation of cells from sputum 
An equivalent volume of Sputolysin (Caldon biotech, USA) was added the ISp sample, 
agitated for twenty minutes at room temperature then, filtered by adding a 100um filter 
into a 50ml conical tube. The filtrate was washed and centrifuged at a centrifugation rate of 
400g for 10 minutes, in phosphate buffered saline (PBS, Philemon Diagnostics) to which 
foetal calf serum (FCS, Sigma Aldrich, USA) was added. Five milliliters of FCS was 
added to each 500ml aliquot of PBS. The supernatant was decanted after washing and 
1500ul of culture medium was added as described below. 
21 
 
2.3.2 Isolation of peripheral blood mononuclear cells (PBMC) 
The anticoagulated blood sample was inverted three times, layered on 4.5 ml histopaque 
(Sigma Aldrich, USA) and centrifuged at 800g for twenty minutes,with the brake off to 
facilitate identification of the buffy coat. The buffy coat was removed with a plastic pipette 
and transferred into a sterile tube. The cells were washed twice, in the PBS plus FCS 
cocktail, by centrifugation at a rate of 400g for 10 minutes with the break on. The cells 
were then stimulated at outlined below. 
 
2.3.3 In vitro antigen stimulation 
The PBMCs and sputum cell preparations were diluted in two millilitres of tissue culture 
medium, RPMI 1640 supplemented with FCS, 2mM L-glutamine GibcoBRL, 100U/ml 
penicillin G and 100ug/ml streptomycin sulphate. All tissue culture reagents were 
purchased from Sigma Aldrich, USA.  
 
During the washing and incubation steps described above, the stimulatory and 
unstimulatory tubes were prepared as follows. Five milliliter polypropylene tubes with 
caps (BD Biosciences, USA) were used for culture. Each blood or ISp sample required 
four culture tubes (PPD, ESAT6, Staphylococcal Enterotoxin B (SEB) and one 
unstimulated). Ten ug/ml of ESAT6 and PPD, both purchased from the Statens 
Seruminstitut, Denmark were added to their respective tubes. We stimulated PBMCs with 
both ESAT6 and PPD to determine whether ESAT6 as a RD1 antigen was more predictive 
of active TB than PPD in a high TB burden country, and to determine whether PPD 
induced significantly more IFNγ than ESAT6. One ug/ml of SEB (Sigma Aldrich, USA) 
was added to the positive control tube. The PPD, ESAT6 and SEB were added to culture 
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media to ensure a final volume of 250ul in each tube. Antigen was omitted from the 
negative control, hence 250ul of culture media was added to the tube marked as ‘negative 
control’. The co-stimulatory cocktail comprised of one microlitre each of co-stimulatory 
antibodies, CD28 and CD49d (Becton Dickinson, USA) as well as 0.5ul Brefeldin A 
(Becton Dickinson, USA), plus culture media to obtain a final volume of 250ul.The co-
stimulatory cocktail was immediately added to all tubes.  Brefeldin A is a cytokine 
secretion inhibitor, hence maintaining IFNγ within the cell so that it could be detected by 
flow cytometry. 
Five hundred microlitres of the cells and tissue culture medium solution was then added to 
each of the four sample tubes. The final sample volume was one milliltre (250ul 
stimulatory mix + 250 co-stimulatory mix + 500ul of the cell solution). The samples were 
gently shaken, then incubated in 5% CO2 for 16 to 18 hours at 37˚C with the cap 
loosened. After stimulation, 100ul ethylenediamine tetra-acetic acid (EDTA) (Becton 
Dickinson, USA) was added, the samples gently shaken and incubated in the dark, at room 
temperature for 15 minutes. This process was performed to detach any adherent cells.  The 
samples were then washed, in PBS supplemented with FCS, by centrifugation at a rate of 
300g for five minutes. The supernatant was decanted. 
  
2.3.4 Fluorescence labelling 
During the incubation and wash steps above, a monoclonal antibody master-mix was 
prepared for surface (CD4Percp Cy3.5 and CD27 APC) and intra-cellular staining (IFNγ 
PE and CD3 FITC). PBS was added to each of the staining mixtures to ensure that 100ul 
could be added to each tube. 
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 One hundred microlitres of the surface markers mixture was added to each of the tubes 
containing the washed cells, and incubated in the dark, at room temperature for 20 minutes. 
Thereafter the cells were washed in PBS supplemented with FCS, by centrifugation at a 
rate of 300g for five minutes. The cells were then permeabilised by adding 250ul of 
Cytofix/Cytoperm (BD Biosciences, USA) to each tube and incubated in the dark, at room 
temperature for 20 minutes. The samples were then washed twice with BD wash buffer 
(included in the cytofix/cytoperm kit, BD Biosciences) by centrifugation at a rate of 500g 
for eight minutes. The supernatant was decanted. 
 
One hundred microlitres of the intra-cellular stain mixture was added to each tube and 
incubated in the dark, at 4˚C for 45 minutes. Following which, the samples were washed 
with BD wash buffer as described above, and Cellfix solution (BD Biosciences) was 
added. The samples were now ready for flow cytometric analysis. CD3, is normally used 
as a surface marker to stain for the T cell receptor (TCR), since is down regulated during 
stimulation, a cytoplasmic CD3 label was used. 
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2.4 Flow cytometry analysis 
2.4.1 Acquisition and quality control 
Four colour flow cytometry was performed on the LSRII flow cytometer (BD 
Biosciences). BD Cytometer set up and tracking beads were run daily which allows the BD 
Facs Diva software to automatically characterise, track and report fluorescent intensities.   
1 X Rainbow beads (Spherotech Inc.), which are mid level fluorescence beads were run 
prior to each experiment in order to standardise the mean fluorescence intensity of each 
flourochrome throughout the duration of the study. Colour spill-over was minimised using 
digital compensation. Compensation refers to the subtraction of light contamination from 
secondary detectors, which occur as a result of spectral overlap. Compensation was 
performed prior to each experiment, using mouse anti-IgG capture compensation beads 
(Becton Dickinson, USA) and calculated digitally using the FacsDiva software. 
Each sample was allowed to run for five to eight minutes. Sample acquisition was stopped 
when the cellular events rate dropped to less than one hundred events so that the full 
volume of the sample was analysed.  
 
2.4.2 Analysis 
Samples were analysed using FloJo software (TreeStar, USA). A  FloJo template was 
created to enable the measurement of percentage IFNγ specific lymphocytes from total 
lymphocytes, CD4+ T lymphocytes and memory CD27- CD4+ T lymphocytes. 
 T lymphocytes were identified by gating on CD3, as CD3+ is a marker for the T cell 
receptor. The gate for each sample set was drawn using the negative control, which is the 
unstimulated blood sample. 
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The percentage IFNγ secreting lymphocytes for each target population outlined above was 
determined utilising a sequential gating strategy, Figures 3.2 to 3.3.  Forward Scatter (FSC) 
Area and FSC Height Plot was used to exclude doublets or clumps of cells. Lymphocytes 
were then identified from their characteristic cluster on side scatter (SSC) and FSC area. 
After gating on the lymphocyte population, the CD3+ and CD4+ co-expressing 
lymphocytes were used to identify the CD4+ T lymphocytes. Finally gating on the CD3+ 
CD4+ lymphocytes with dim to absent expression of CD27 identified the memory, CD27- 
CD4+ T lymphocytes.  
 
2.5 Diagnostic classification  
TB culture is the current ‘gold standard’ used to diagnose active disease. A microbiological 
classification was therefore used to categorise the study population. All participants were 
smear negative at enrolment but were being investigated for active TB, hence repeat 
sputum microscopy as well as TB culture were requested on sputum or other tissue from 
all study  participants.  These results were used to assign final diagnosis as follows: 
• M. tuberculosis Positive/Active TB: patients who have positive microscopy or 
culture results subsequent to enrolment. 
• M. tuberculosis Negative/Latent or non-TB: patients who remain microscopy and 
culture negative. 
Flow cytometric detection of IFNγ responses from blood or ISp lymphocytes were 
statistically analysed to determine whether these responses could be used to discriminate 
between the M.tuberculosis negative and positive groups 
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2.6 Data analysis  
The percentage of IFNγ producing cells was determined for each cellular population. Tests 
for normality were performed on all data to be analysed, leading to use of non-parametric 
statistics for all data that was not normally distributed. Data was summarized using 
descriptive non-parametric statistics such as median values. The Mann-Whitney test was 
used to compare IFNγ production between groups.  A value of p < 0.05 was considered 
significant. A receiver operating curve was used to establish sensitivity and specificity. 
Correlations were calculated by non-parametric Spearman’s test. GraphPad Prism version 
5 was used for all statistical analyses and to draw graphs. 
Data was analysed as raw values, and with the unstimulated background IFNγ secretion 
subtracted from the stimulated values. Only the raw data has been reported.  The subtracted 
data showed similar trends.  
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CHAPTER THREE 
3.0 Results 
3.1.0 Optimisation of laboratory techniques 
3.1.1 Titration of monoclonal antibodies 
 Each monoclonal antibody in the panel was titrated to identify the minimum volume that 
could be used to provide good quality results while limiting the expense of these 
antibodies. Table 3.1 represents the results of the titration experiment for CD27 APC 
where a final volume of 10ul was selected as this volume produced the best S:N ratio.The 
titration volumes obtained for CD27 APC, CD4 PerCP Cy3.5, CD3 FITC and IFNγ PE 
were 10ul, 15ul, 10ul and 15ul respectively.  
 
Table 3.1 Analysis of CD27 APC titration. For CD27 APC, this table shows the increase 
in the mean fluorescence intensities of both the positive population (signal) and the 
negative population (noise) with increasing volumes of antibody used, as well as the 
calculated signal to noise ratio. 
 CD27 APC 
 NegMed PosMed S:N 
 CD27 APC  2.5uL 31.7 1979 62.43 
 CD27 APC 5uL 50 4039 80.78 
CD27 APC  10uL 54.6 5438 99.60 
CD27 APC  20uL 72.5 6452 88.99 
CD27 APC  40uL 83.2 6607 77.55 
CD27 APC 80uL 99.7 6945 69.66 
 
 
 
 
 
The optimal signal to noise ratio is highlighted in red. The first column shows the 
phenotypic marker, the fluorescent label followed by the clone of the monoclonal antibody 
then titration volume. 
NegMed, negative median. PosMed, positive median. S:N, signal to noise ratio 
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3.1.2 FMO experiment 
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Figure 3.1 Flow cytometry dot-plots of the FMO experiment 
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3.1.4 Concentration of ESAT6 and PPD used to stimulate the samples 
PPD and ESAT6 were each evaluated at two concentrations, five ug/ml and ten ug/ml, for 
maximal IFNγ secretion by a healthy control individual. Table 3.2 shows the PE (IFNγ) 
MFI produced after stimulation with either five ug/ml or ten ug/ml of PPD and ESAT6. 
The MFI values from the 10ug/ml concentration produced marginally higher MFI values 
than the five ug/ml concentration. Ten ug/ml each of PPD and ESAT6 was selected as the 
concentration with which to stimulate further samples.  
 
Table 3.2 IFNγ Mean Fluorescence Intensity after stimulation with ESAT6 and PPD 
Concentration of Antigen (ug/ml) IFNγ MFI 
ESAT6 5 911
ESAT6 10 948 
PPD 5 1051 
PPD 10 1158 
Mean fluorescence intensity (MFI) for both PPD and ESAT6 was marginally higher using 
10ug/ml than 5ug/ml  
 
 
3.1.5 Quantitation of M. tuberculosis specific IFNγ secreting lymphocytes in blood and 
sputum 
All participants produced IFNγ in response to SEB, which was used as the positive control. 
For blood samples, IFNγ secreting lymphocytes were quantified as a frequency of total 
lymphocytes, CD4 + T lymphocytes or memory, CD27- CD4+ T lymphocytes, Figures 3.2 
to 3.5 respectively. For sputum, samples only IFNγ secretion as a frequency of total 
lymphocytes was included in the statistical analysis, as numbers of IFNγ events in the 
CD4+ or CD27- CD4+ T lymphocyte subsets became too small for reliable interpretation, 
Figure 3.2. Gates for IFNγ positivity were set according to the unstimulated sample and 
copied into the stimulated tubes.  
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3.2 Study population 
Thirty-one HIV infected, smear negative TB suspects who met the inclusion and exclusion 
criteria were recruited, including five from HJH and twenty-six from CMJAH. Blood 
samples were analysed on all 31 patients. One patient was unable to expectorate following 
sputum induction. Despite optimisation of sputum processing techniques, eleven sputum 
samples were excluded due to assay related factors including poor lymphocyte viability 
and the presence of non-specific monoclonal binding, leaving nineteen samples  suitable 
for analysis. According to the diagnostic classification outlined in section 2.5, seventeen 
patients were classified as M. tuberculosis positive and fourteen were classified as M. 
tuberculosis negative from the whole group. Of the 19 patients with available sputum 
samples, 9 were M. tuberculosis positive and 10 M. tuberculosis negative. The diagnosis of 
positivity was made either on AFB smears or culture of M. tuberculosis from the ISp 
sample taken during this study or subsequent samples from any site. PCR analysis 
(GenoType MTBDR, Hain Lifesciences, Germany) of all positive results confirmed the 
isolates as M. tuberculosis. All patients were suspected of having pulmonary TB, while 
four patients were subsequently found to have additional extra pulmonary sites of M. 
tuberculosis. 
 
 The relevant patient information is summarised in Table 3.3. The study population 
comprised 48% females and 35% were on anti-retroviral therapy. The median age of the 
study population was 37 years old (range, 17 to 61 years) and the median CD4 count was 
117 cells/ul (range, 15 to 503 cells/ul). IFNγ secretion from blood lymphocytes showed no 
correlation with CD4 count or age (data not shown). 
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Table 3.3 Summary of patient characteristics 
STUDY 
NO. 
HOSPITAL AGE SEX DATE of 
PREVIOUS 
TB 
(treatment 
duration) 
HAART ? EXTRA 
PULMONARY 
M. tuberculosis 
CD4 AFB/CULTURE 
RESULTS 
1 HJH 61 female no no no - Negative 
2 HJH 39 female yes- 2008 
(6/12) 
yes no 229 Negative 
3 HJH 53 female no no no 276 Negative 
4* HJH 50 female no no yes - shoulder 
abscess AFB 
positive 
- Positive - 
shoulder abscess 
5* HJH 54 female no no cervical lymph 
nodes 
- Positive - cervical 
lymph node 
6 CMJAH 49 female unknown 
(1/52 in Feb 
2010) 
no no 43 Negative 
7* CMJAH 27 male no no no 88 Negative 
8* CMJAH 28 male no yes no - Negative 
9 CMJAH 25 male yes - 2006 
(6/12) 
yes no 112 Negative 
10* CMJAH 36 male no yes no 57 Positive – sputum 
11* CMJAH 35 male no yes no 178 Positive - cervical 
lymph node 
12 CMJAH 36 female no no no 185 Negative 
13 CMJAH 52 male no no ?TB Meningitis 45 Positive - pleural 
fluid and BMA 
14 CMJAH 33 male no yes no 49 Negative ( but 
high fluid ADA) 
15 CMJAH 39 male yes - 2007 
(6/12) 
no ? Miliary - Positive – sputum 
16* CMJAH 54 female no no no 252.5 Positive – sputum 
17 CMJAH 35 female yes - 2007 
(6/12) 
no no 15 Positive – sputum 
18 CMJAH 17 male no no no - Positive – sputum 
19 CMJAH 34 female no no no 193 Positive – sputum 
20* CMJAH 29 male no no no - Positive – sputum 
21 CMJAH 39 female yes - 2008 
(6/12) 
yes no - Negative 
22* CMJAH 35 male  no ? TB Meningitis 173 Negative 
23* CMJAH 34 female yes-2008 
(6/12) 
yes no 111 Negative 
24 CMJAH 28 female no yes no 122 Positive – sputum 
25 CMJAH 34 male yes- 2008 
(6/12) 
no no 56 Negative (but 
marked 
inflammatory  
infiltrate) 
26 CMJAH 41 male yes - 2007 
(6/12) 
yes no 152 Positive – sputum 
27* CMJAH 51 male no no no 51 Positive – sputum 
28 CMJAH 29 female no yes no 500 Negative 
29 CMJAH 40 male no no no 25 Positive – sputum 
30 CMJAH 30 female no no yes - ?TB 
Meningitis 
503 Positive – sputum 
31* CMJAH 30 male no no no 150 Positive – sputum 
 HAART, Highly Active Antiretroviral therapy. ADA, Adenosine Deaminase. BMA, bone 
marrow aspirate.* indicates patients in whom only blood was available for analysis, as 
sputum was not available or suitable for meaningful interpretation. ? indicates unknown or 
possible 
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3.3 Cell yield in blood and sputum samples  
The mean number of lymphocyte acquired varied amongst samples but sputum samples 
produced a lower mean than blood samples. The mean number of lymphocytes acquired 
for each of the lymphocyte populations in the unstimulated sample for blood and sputum 
are tabulated in Table 3.4.  
 
 
Table 3.4 Mean lymphocyte counts acquired from the unstimulated tubes for blood 
and sputum 
LYMPHOCYTE 
POPULATION 
M. TUBERCULOSIS 
POSITIVE  
(MEAN CELL NUMBER)
M. TUBERCULOSIS 
NEGATIVE 
 (MEAN CELL NUMBER) 
Blood (n=31) 
Total lymphocytes  
(range) 
218252
(18452 - 468361)
269108
(45428 – 683946)
CD4+ T lymphocytes  
(range) 
58539
(319 - 291471)
48951
(3084 – 237097)
CD27- CD4+ T 
Lymphocytes  
(range) 
7363
(113 – 34516) 
15190
(298 – 10077) 
 Sputum (n=31)     
Total lymphocytes  
(range) 
41970
(37 – 156939)
30261
(539 – 184662)
CD4+ T lymphocytes 
  
Insufficient to gate Insufficient to gate
CD27- CD4+ T 
lymphocytes  
 
Insufficient to gate Insufficient to gate
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3.4 The effect of M. tuberculosis antigen stimulation in blood and sputum 
The percentage of IFNγ secretion was quantified as described in 3.1.3. The percentage of 
M. tuberculosis specific IFNγ secreting lymphocytes in blood and sputum of the M. 
tuberculosis positive and negative groups were compared to that from the respective 
unstimulated samples to determine whether IFNγ secretion was largely antigen specific. 
Figures 3.6 and 3.7 show the comparison between the percentage of M. tuberculosis 
specific (stimulation with either PPD or ESAT6) and non-specific (unstimulated samples) 
IFNγ secreting total lymphocytes in blood and sputum samples. 
 
In the blood samples from the M. tuberculosis positive group Figure 3.6.A, the median 
PPD (0.15%) specific or ESAT6 (0.12%) specific  IFNγ secreting lymphocytes were 
significantly higher than the unstimulated sample (0.03%. p = 0.006 and p = 0.009 
respectively). In the blood samples from the M. tuberculosis negative group, Figure 3.6.B, 
the median PPD (0.20%) specific IFNγ secreting lymphocytes  remained significantly 
higher than the median from the unstimulated sample (0.08%. p = 0.03)  but this 
significance (p,0.35) was not noted when  ESAT6 (median,0.09%) was used as the 
stimulant.  
 
In sputum, Figure 3.7, median PPD specific and ESAT6 specific responses were not 
significantly higher than the unstimulated samples for either the M. tuberculosis positive or 
negative groups. The median percentage PPD, ESAT6 and unstimulated IFNγ secreting 
lymphocytes in the M. tuberculosis positive were 0.23%, 0.64% and 0.27% respectively,  
and in the M. tuberculosis negative group were 2.04%, 3.18% and 2.08% respectively.  
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Figure 3.6 IFNγ secretion as a percentage of total lymphocytes in unstimulated 
samples and following stimulation with either ESAT6 or PPD in blood 
 In the M. tuberculosis positive (A) group, PPD and ESAT6 specific IFNγ secretion is 
significantly higher than the unstimulated samples. In the M. tuberculosis negative (B) 
group, PPD but not ESAT6 specific IFNγ secretion was significantly higher than the 
unstimulated samples. No significant differences were noted between ESAT6 and PPD in 
their ability to induce IFNγ secretion. Median % PPD and ESAT6 specific and 
unstimulated IFNγ responses in M. tuberculosis positive are 0.15%, 0.12% and 0.03% 
respectively and median responses in M. tuberculosis negative  are 0.20%, 0.09% and 
0.08% . Blood, n = 31. 
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3.5 Comparison of PPD and ESAT6 as optimal stimuli for IFNγ induction 
 
 
We compared the magnitude of the IFNγ response by lymphocytes in blood and sputum to 
assess which antigen was the more powerful stimulant. The two stimuli were compared in 
the M. tuberculosis positive and negative groups. Data representing the frequency of M. 
tuberculosis specific IFNγ secreting lymphocyte as a percentage of total lymphocytes in 
both blood and sputum is shown in Figure 3.6 and 3.7 respectively. This analysis shows 
that IFNγ  induction by total blood and sputum lymphocytes was not significantly different 
when stimulated with either PPD or ESAT6. Similarly, in blood, there was no significant 
difference in the two stimuli for IFNγ production by CD4+ T lymphocytes or memory 
CD27- CD4+ T lymphocytes in any patient group analysed (data not shown).  
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Figure 3.7 IFNγ secretion as a percentage of total lymphocytes in the unstimulated 
samples and following stimulation with either ESAT6 or PPD in sputum.  
IFNγ secretion does not show statistical differences between the unstimulated and 
stimulated samples. No significant differences were noted between ESAT6 and PPD in 
their ability to induce IFNγ secretion. Median % PPD and ESAT6 specific and 
unstimulated  IFNγ responses in M. tuberculosis positive (A) is 0.23%, 0.64% and 0.27% 
respectively; and  2.04%, 3.13% and 2.08%  respectively in the M. tuberculosis negative 
(B) population. Sputum, n=19. 
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3.6 IFNγ secretion from sputum is higher than blood 
The percentage of IFNγ secreting lymphocytes as a frequency of total blood lymphocytes 
was compared to the frequency of the total sputum lymphocytes to determine whether the 
lung produced significantly more IFNγ. Only blood samples with corresponding sputum 
samples were used in this analysis (n=19). This data is represented in Figure 3.8. The 
median percentage of ESAT6 specific IFNγ secreting lymphocytes in blood and sputum 
were 0.10% and 0.64% respectively in the M. tuberculosis positive group and, 0.10% and 
3.18% respectively in the M. tuberculosis negative group. The median PPD specific IFNγ 
secreting lymphocytes in blood and sputum were 0.15% and 0.23% respectively in the M. 
tuberculosis positive group and, 0.21% and 2.04% in the M. tuberculosis negative group 
respectively. Thus, the percentage of M. tuberculosis specific IFNγ secreting lymphocytes 
was   higher in sputum than blood. The difference between blood and sputum was 
significantly different in the M. tuberculosis positive group when stimulated with ESAT6 
(p = 0.03) but in the M. tuberculosis negative group the difference was significant after 
PPD stimulation (p = 0.006). Comparison of SEB specific IFNγ secreting lymphocytes in 
blood and sputum was not significantly different (data not represented, p= 0.48). 
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Figure 3.8 ESAT6 and PPD specific IFNγ secreting lymphocytes in blood and sputum 
of both the M. tuberculosis positive and negative groups 
M. tuberculosis specific lymphocytes were more frequent in sputum compared to blood, 
reaching statistical significance in the M. tuberculosis positive group with ESAT6, and 
with PPD stimulation in the M. tuberculosis negative group. Sputum PPD specific IFNγ 
secreting lymphocytes were significantly higher in the M. tuberculosis negative group 
when compared to the M. tuberculosis positive group. Only blood samples with 
corresponding sputum samples were analysed (n=19).  
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3.7.0 Comparison of IFNγ secretion in sputum and blood to final microbiological 
diagnosis 
In order to assess whether IFNγ responses could be used diagnostically, we compared the 
results to the microbiological tests and used the diagnostic classification outlined above. 
The percentage of IFNγ secreting lymphocytes in sputum and blood of the M. tuberculosis 
positive group was compared to that of the M. tuberculosis negative group to determine 
whether this approach could be used to differentiate active TB from background 
mycobacterial exposure in a TB endemic setting. Lung based samples were shown to be 
capable of differentiating active and latent TB in low prevalance settings. In addition blood 
memory CD4+ T lymphocytes which are characterised as being CD27- have been shown 
to differentiate activate TB from latently infected or unexposed individuals.  
 
3.7.1 PPD but not ESAT6 specific IFNγ responses in sputum differentiates M. 
tuberculosis positive and negative patients  
In the ISp, PPD stimulation resulted in significantly more IFNγ secretion in the M. 
tuberculosis negative group than the M. tuberculosis positive group, Figure 3.8. The 
median percentage of PPD specific IFNγ secreting lymphocytes were 2.04% in the M. 
tuberculosis negative group and 0.23% in the M. tuberculosis positive group.  
 
Stimulation with ESAT6 resulted in higher specific IFNγ secretion in the in the M. 
tuberculosis negative (median, 3.18%) compared with the M. tuberculosis positive group  
(median, 0.64 %). However this did not reach significance (Figure 3.8). 
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3.7.2 Sensitivity and specificity of PPD specific lymphocytes in sputum to differentiate 
M. tuberculosis positive and negative patients 
A receiver operating curve (ROC), Figure 3.9, was generated to calculate the cut-off value 
for sputum PPD stimulated IFNγ production with the best sensitivity and specificity for 
diagnosis of active TB. A frequency of PPD specific IFNγ secreting lymphocytes at a 
diagnostic threshold of 1.20 % had a sensitivity of 78% (95% CI, 40% to 97) and 
specificity of 70% (95% CI, 35% to 93%) to discriminate smear or culture positive  M. 
tuberculosis from smear and culture negative M. tuberculosis. The area under the curve 
was 0.78. The positive and negative predictive values are 70% and 78%, respectively, 
Table 3.9. 
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 Figure 3.9 ROC curve analysis of sputum PPD induced IFNγ production  
The sensitivity and specificity for discriminating smear or culture positive M. tuberculosis 
from smear and culture negative M. tuberculosis by percentage PPD specific IFNγ 
secretion from sputum lymphocytes, at a diagnostic threshold of 1.20, larger red point, are 
78% and 70%, respectively.  
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Table 3.5   Two by Two table to calculate sensitivity, specificity and predictive values 
Sputum PPD specific IFNγ M. tuberculosis Positive M. tuberculosis Negative 
Positive  7 (TP) 3 (FP) 
Negative 2(FN) 7(TN) 
 Using a diagnostic threshold of 1.20 % PPD specific IFNγ secreting lymphocytes in 
sputum, the assay correctly diagnosed 7 patients with active TB (true positive, TP), 
incorrectly diagnosed 3 patients without active TB as having TB (false positive FP);  
incorrectly missed the diagnosis of active TB in 2 patients (false negative, FN) and was 
correctly negative in 7 patients without active TB (true negative, TN). The sensitivity is 
78%, specificity is 70% and positive and negative predictive values are 70% and 78% 
respectively. 
 
 
3.7.3 M. tuberculosis specific IFNγ responses in blood failed to differentiate the M. 
tuberculosis positive and negative patients 
In blood, the percentage of ESAT6 or PPD specific IFNγ secreting lymphocytes (total, 
CD4+ T lymphocytes or memory CD27- CD4+ T lymphocytes) were not statistically 
different when the M. tuberculosis positive or negative groups were compared, Figure 
3.10. The median percentage ESAT6 specific IFNγ secreting total lymphocytes was 0.12 
% versus 0.09%, 1.54 % versus 1.07% for CD4+ T lymphocytes and 1.17% versus 2.3% 
for CD27- CD4+  T lymphocytes for the M. tuberculosis positive and negative groups 
respectively. The median PPD  specific IFNγ secretion was 0.15% versus 0.20% for total 
lymphocytes,  1.20%  versus 0.58% for CD4+ T lymphocytes and 2.50% versus 2.96% 
CD27- CD4+ T lymphocytes for the M. tuberculosis positive and negative groups 
respectively. All these comparisons between the M. tuberculosis positive and negative 
groups produced p > 0.30. 
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Figure 3.10 ESAT6 (A) and PPD (B) specific IFNγ secreting total, CD4+ and CD27- 
CD4+ blood T lymphocytes in M. tuberculosis positive and negative patients  
No statistical differences were noted between the two TB groups for any of the lymphocyte 
populations analysed. Blood, n = 31. 
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3.8 IFNγ secretion from CD27- CD4+ T lymphocytes compared to CD27+ CD4+ T 
lymphocytes 
CD27- CD4+ T lymphocytes in this study did not differentiate the active from the latent 
group. This lead us to investigate the secretion of IFNγ from the two CD27 subsets and to 
determine whether IFNγ secretion from CD27+ CD4+ T lymphocytes, rather than the 
CD27- subset, was more informative in our cohort. No difference was noted in ESAT6 
stimulated IFNγ secretion by the CD27+ CD4+ T lymphocytes between the M. 
tuberculosis positive and negative groups (data not shown).  Interestingly, as shown in 
Figure 3.11, a higher percentage of IFNγ was secreted by the CD27+ CD4+ T lymphocytes 
than the the CD27- CD4+ T lymphocytes in both the M. tuberculosis positive (median 
0.37% ) and M. tuberculosis negative groups (median = 0.2% ) groups (p= 0.01).However, 
when samples were stimulated with PPD, no difference was observed between the 
percentage for both the M. tuberculosis positive (median CD27+ is 0.12% and CD27- is 
0.44%) and negative populations (median CD27+ is 0.12% and CD27- is 0.26%).  
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Figure 3.11 IFNγ secretion from CD27 CD4+ T lymphocytes after stimulation with 
ESAT6 and PPD 
ESAT6 specific IFNγ CD4+ T lymphocytes are predominantly CD27+ but PPD specific 
IFNγ CD4+ T cells can be either CD27+ or CD27- . 
Blood, n=31. 
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CHAPTER FOUR 
4.0 Discussion and Conclusion 
4.1 Discussion 
The HIV epidemic in South Africa has not only lead to a resurgence of TB but has also 
impacted on the TB diagnostic approach, by emphasizing the need for assays that do not 
rely on the detection or culture of acid fast bacilli (5). The present study was undertaken to 
improve the understanding of M. tuberculosis lung specific T cell immune responses and to 
explore the role of flow cytometry in the immuno-diagnosis of active TB disease in a 
setting with a high prevalence of HIV and M. tuberculosis co-infection. 
 
The study population represented the most diagnostically challenging group who gravely 
require new diagnostic approaches, that is HIV positive individuals admitted with a clinical 
suspicion of active TB but who are initial sputum smear AFB negative. A microbiological 
classification was used to categorise patients as M. tuberculosis positive (n = 17 for blood, 
n = 9 for sputum) and M. tuberculosis negative (n = 14 for blood, n = 10 for sputum) on 
the basis of their subsequent smear microscopy and culture results. The M. tuberculosis 
negative group served as the control group, which is clinically more relevant for evaluation 
of novel diagnostic approaches than using a healthy control group, in a high TB burden 
setting such as this. 
 
We optimised a simple four colour flow cytometry panel to identify IFNγ secreting 
lymphocytes in the blood and sputum of HIV and M. tuberculosis co-infected individuals. 
This study confirmed that M. tuberculosis specific IFNγ secreting lymphocytes are 
concentrated in the lung. The frequency of M. tuberculosis specific IFNγ secreting 
lymphocytes in sputum was higher than that of blood. This finding most likely reflects the 
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potency of the immune response at the primary site of infection, the lung (9). The most 
significant finding however, is that the percentage of PPD specific IFNγ secreting sputum 
lymphocytes is significantly higher in the M. tuberculosis negative group than the  M. 
tuberculosis positive group. The sensitivity and specificity of this method at a diagnostic 
threshold of 1.20% to diagnose microbiological proven TB in a high prevalence setting is 
78% and 70% respectively, yielding a positive and negative predictive value of 70% and 
78% respectively. 
 
 The higher percentage of IFNγ secretion in the M. tuberculosis negative  group was 
counterintuitive at first, and is contradictory to the findings by Breen et al (9). This 
contradictory result can be attributed to the differences in the study population, with the 
Breen study population being drawn from an area of low M. tuberculosis prevalence with 
only three patients having latent infection.  Two of  the three latently infected individuals, 
and who were recently infected  produced IFNγ responses higher than fifty percent of the 
active TB group (9) . Of interest, latent TB infection has been shown in other studies (47) 
(48) to produce higher percentages of M. tuberculosis specific IFNγ secreting lymphocytes 
than active disease. A recent publication (48) analysed the immune responses from T 
lymphocytes in individuals with active and latent M. tuberculosis infection and concluded 
that patients with latent TB had polyfunctional T lymphocyte immune responses, including 
IFNγ production but T lymphocytes from patients with active TB had single TNFα 
positivity. This shows that patients with latent TB infection produced IFNγ but patients 
with active disease did not, they only produced TNFα.  The same conclusion was drawn by 
a similar study (47) who found reduced PPD specific T lymphocytes in active TB when 
compared to latent infection.    
 
52 
 
Accurate data on the prevalence of latent TB in South Africa is not available but ranges 
from 55 to 88%  according to data published by local investigators (13) (49) (50).  This 
equates to a possible large proportion of latently infected individuals in the M. tuberculosis 
negative group of this study. Hence, the Breen study (9)  compared active disease largely 
to unexposed individuals, and the current study compared active M. tuberculosis to a 
mixed group, which is likely  to comprise  largely of latently infected individuals. We 
believe that these latently infected individuals in the M. tuberculosis negative group, of this 
current study, are responsible for the high IFNγ secretion noted after stimulation with PPD. 
 
We showed that PPD and ESAT6 were of similar ability to induce IFNγ secretion in blood 
and though both antigens induced significantly more IFNγ in the M. tuberculosis positive 
group, only PPD reached this significance in the M. tuberculosis negative group. Sputum 
IFNγ responses to either antigen were higher in sputum than in blood, this difference 
reached significance for PPD in the M. tuberculosis negative and ESAT6 in the M. 
tuberculosis positive group. The implications of these findings are not clear and may 
simply reflect small sample size or these differences highlight the complexity of measuring 
the immune responses in settings where there is a high prevalence of both M. tuberculosis 
and MOTTs as well as the routine practise of BCG vaccination. The choice of antigen to 
be used in future studies therefore requires careful consideration and should be based on 
influencing factors such as the use of PPD when analysing blood based samples in areas 
where administration of the BCG vaccine is routine practise.   
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M. tuberculosis specific CD27- CD4+ T lymphocytes, as  a marker of memory CD4+ T 
lymphocytes, has gained recognition as quick blood based tool to diagnose active TB  (8). 
Sreitz et al (45)  showed that PPD specific IFNγ production from blood CD27- CD4+ T 
lymphocytes served as a marker for active M. tuberculosis disease (sensitivity 100% and 
specificity of 85%).  The current study  however, did not detect any difference  in antigen 
specific IFNγ production from  blood CD27- CD4+ T lymphocytes between the M. 
tuberculosis positive and M. tuberculosis negative populations that has been previously 
described (45) (51).   The possible explanation for this discrepancy is that the population in 
previous studies differed from the current study. All participants in the current study are 
HIV positive, and HIV infection can alter CD27 expression and subsequent proliferation of 
antigen specific CD4+ T lymphocytes (52).  In addition, HIV and M. tuberculosis co-
infection is associated with paucibacillary disease (25) and the loss of CD27 expression on 
CD4+ T lymphocytes may be linked to the bacterial burden of the disease in the lung (45). 
Furthermore, a recent study showed that the reduced expression of CD27 on M. 
tuberculosis specific CD4+ T lymphocytes correlates better with persistent active TB 
rather than newly diagnosed active TB (51).  All participants in this study were individuals 
with newly diagnosed active TB, rather than persistent active disease. Our patient cohort 
represents the type of patient commonly posing diagnostic difficulties in our setting, and is 
a group of individuals at risk of increased morbidity and mortality as well as at risk of 
spreading the infection to other susceptible individuals (4) (5) (6). 
 
An interesting finding is that in the M. tuberculosis positive group, ESAT6 specific CD27+ 
CD4+ T lymphocytes produced significantly more IFNγ than the corresponding CD27- 
population. This finding is similar to other studies performed in humans but contrary to the 
murine model (51).  IFNγ secretion from CD27 subsets after stimulation with PPD did not 
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show similar significant differences, which probably highlights the cross reactivity 
between the BCG vaccine and PPD antigens. A similar study (45) showed that the BCG 
vaccine alone, in unexposed individuals resulted in 35% CD27- PPD specific CD4+ T 
lymphocytes. These findings show that the inclusion of CD27, as a marker of memory T 
cells, into a flow cytometric panel for IFNγ production does not aid TB diagnosis of newly 
acquired active M. tuberculosis infection in a high prevalence setting.  
 
The limitations of this study need to be addressed. The effect of LTBI in the M. 
tuberculosis negative group cannot be quantified, as latency was not diagnosed. Due to 
ethical and financial constraints, in this cross-sectional study, the author would have been 
unable to provide Isoniazid prophylaxis to latently infected subjects with appropriate 
monitoring, and it was therefore decided not to include tests for latency. BCG vaccination 
status was not documented despite enquiry, as patient self–reporting for a vaccine 
administered at birth was unreliable. However, BCG vaccination at birth forms part of the  
South African immunisation schedule implying that most if not all participants were 
vaccinated.  The sample number (n=31 blood; n=19 sputum) was limited due to financial 
constraints imposed by the high cost of monoclonal antibodies and other reagents. 
Secondly, all tasks, from obtaining informed consent and collecting samples to preparing 
and analysing these samples were performed by the author. Sputum sample numbers were 
further reduced since samples had to be excluded (n = 11) due to quality and technical 
processing issues. The exclusion of sputum samples was performed independently of the 
microbiological results. The need to perform a Bartlett score to assess the quality of the 
sputum samples was overlooked. This would have enabled the exclusion of the unsuitable 
sputum samples prior to processing. In addition, frequent unstimulated IFNγ secretion was 
noted in sputum samples and a viability marker was not added to sputum samples to 
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exclude the effect of dead cells binding non-specifically to the fluorescent labelled 
monoclonal antibodies. However, most debris was excluded using the FSC-A: FSC-H plot 
and gating strategy described above. Finally, the sensitivity of smear microscopy and 
culture, even on ISp, is not 100% hence some of the patients in the M. tuberculosis  
negative group could have been misclassified.  The Xpert MTB/RIF (GeneXpert, Cepheid) 
was not routinely performed at the time of this study, and inclusion of the Xpert MTB/RIF 
(GeneXpert, Cepheid) would have improved reliability of the sputum results.  
 
The strengths of this study include the study population and sample choice. The study 
population reflects the group of patients in which new diagnostic approaches are needed, 
which is HIV positive individuals from a high TB endemic setting who are AFB sputum 
negative. Furthermore, as explained above the culture negative control group comprised a 
clinically more relevant group than using healthy individuals. The use of both blood and 
sputum samples enabled the comparison of the immune response at these two 
immunologically distinct compartments. 
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4.2 Conclusion 
We have shown that in HIV M. tuberculosis co-infected individuals, immune responses in 
ISp samples can be quantified using flow cytometry techniques. Lung responses showed 
differences between the M. tuberculosis positive group and the M. tuberculosis negative 
group, while these findings were not reproduced in blood even with inclusion of the 
memory marker, CD27.  
Sputum samples offer the following advantages over blood samples, that is, the proportion 
of M. tuberculosis specific IFNγ secreting lymphocytes is higher, the sample is less 
affected by BCG vaccination and the sample can be split for microbiological assessment. 
Sputum induction is a simple non-invasive procedure that can easily be performed in an 
out-patient department. However similar to the recommendations made by a study that 
used the immunospot system to evaluate IFNγ responses in induced  sputum (53), we 
believe that measuring immune responses in sputum based assays is unlikely to be useful 
in the routine diagnostic setting. The impracticalities of this method include the logistical 
difficulties involved in processing sputum for flow cytometry analysis, as samples need to 
be processed within two hours and despite meeting this requirement often display a paucity 
of cellular content. Furthermore, the newly introduced molecular testing methods offer a 
more robust, less labour intensive system with the added advantage of drug susceptibility 
testing with comparable sensitivity and specificity for sputum smear negative samples. 
Nonetheless, these results will assist in increasing the understanding of the lung 
compartment-specific immune response to TB in high prevalence settings and our 
understanding of TB pathogenesis and the spectrum of TB specific T lymphocyte immune 
responses as one progresses from latent to active disease. The finding of lower IFNγ 
secretion in the lung compartment in the M. tuberculosis positive group after stimulation 
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with PPD in comparison with the M. tuberculosis negative group was counter-intuitive, as 
most blood based assays and a handful of studies analyzing lung specific immune 
responses have reported increased IFNγ secretion in the TB group in comparison with the 
control group. This is likely due to a difference in the control group used, with our control 
group likely having a high prevalence of latent TB and prior studies largely being 
conducted in areas of low latent TB prevalence. The finding of lower M. tuberculosis 
specific IFNγ secretion in active TB is supported by the findings of Harari (47) and Streitz 
(48) et al, both of whom also compared the T lymphocyte immune responses in active TB 
to that of latent infection. These studies however used blood rather than lung based 
samples. It has been proposed (48) that the reduced IFNγ secreting lymphocytes in the 
blood of patients with active TB represents either a diminished response or trafficking of 
these IFNγ secreting cells from the blood to the lung. Our finding supports the theory that 
as an individual progresses from latent infection to active TB the ability to produce IFNγ is 
diminished.   
We hypothesise from these findings that the percentage of M. tuberculosis specific IFNγ  
secreting lymphocytes is a spectrum ranging from low in unexposed individuals to 
intermediate in active disease to high in latent TB infection, and that the reduced IFNγ 
secretion in active disease when compared to latent infection reflects the loss of protection 
as one progresses from latent to active TB. Furthermore, our findings highlight the 
importance of studying compartment specific immune responses rather than blood alone, 
and we recommend more studies in high TB prevalent settings adopt this approach to 
elucidate the spectrum of IFNγ secretion from latency to active TB.  
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APPENDIX 2: Patient Information Sheet 
 
STUDY NUMBER:   
 
STUDY TITLE: 
 Diagnosis of active tuberculosis using flow cytometry in HIV infected individuals in a 
tuberculosis (TB) endemic setting 
 
 
INVESTIGATOR: Dr S Buldeo 
 
INSTITUTION: NHLS 
 
DAYTIME AND AFTER HOURS TELEPHONE NUMBER(S):  
              Dr Suvarna Buldeo 011 4898432/ 0833053665 
 
 
INTRODUCTION: 
Good  day,  my  name  is  Dr  Suvarna  Buldeo,  I  am  a  doctor  currently  specialising  in 
Clinical  Pathology  and  am  currently  working  in  the  Haematology  department  at 
Johannesburg General Hospital. I would like to invite you to consider participating in 
a research study, entitled “Immunodiagnosis of active tuberculosis (TB)using Induced 
sputum and blood in HIV infected individuals in a TB endemic setting”. 
• You  have  presented  with  a  cough,  fever  and/or  night  sweats.  This  could 
 
possibly be TB. 
• TB  is  treatable  and  curable  but  patients  need  to  take  anti‐TB  drugs  for  six 
months or longer.  Many complications can occur if the diagnosis is not made 
promptly and treatment initiated timeously. 
• Diagnosis of TB is difficult and takes a long time. This is especially true in HIV 
positive people as they do not present with the classical signs and symptoms. 
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The purpose of this study is to determine if TB diagnosis can be improved.   
• This  study will  use  induced  sputum  and  a  blood  sample  to  aid  in  the  rapid 
diagnosis  of  TB.  I  will  shortly  explain  the  procedure  for  induced  sputum  to 
you.  We are investigating a new assay using these samples. It is an assay using 
that  will  use  the  techniques  of  flow  cytometry  to  evaluate  the  immune 
response  to TB.   This may assist  in determining whether a person has TB or 
not, sooner than the tests that are currently available. These samples will also 
be sent for TB culture, which is the gold standard for TB diagnosis. The culture 
esults will therefore be used to assess if a person definitively has TB. r
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immediately.  
• Your blood and sputum will be sent for TB microscopy and culture as well as 
the new  test  under  investigation  in  this  study  that  is  flow  cytometry. At  the 
end  of  the  study  left‐over  blood  and/or  sputum  may  be  stored  for  future 
testing. This may include genetic testing related to HIV and/or TB and ethics 
approval will be sought prior to use. 
 
 
LENGTH OF THE STUDY AND NUMBER OF PARTICIPANTS: 
•  year to the end of next year. The study will be performed from November this
• ted. Approximately 50 participants will be recrui
• The participants will be 18 years and older.  
• The total amount of time required for your participation in this study will be a 
maximum of six hours today and another short visit in eight weeks. 
• You will  be  asked  to  re‐visit me  in  eight weeks  for  the  results  of  your  tests 
(microscopy and culture of induced sputum). 
 
 
  PROCEDURES: 
• If  you  agree  to  take part  in  this  study,  you will  first  be  asked questions  and 
examined to see if you qualify for this study. 
• Please  note  that  one  tube  of  blood  and  an  induced  sputum  sample  are 
o arequired. This may result in minor discomfort but should n t c use any pain.  
• Venipunctures  (i.e.  drawing  blood)  are  normally  done  as  part  of  routine 
medical care and present a slight risk of discomfort.  Drawing blood may result 
in  faintness,  inflammation  of  the  vein,  pain,  bruising  or  bleeding  at  the 
puncture site. There is also a slight possibility of infection. Your protection is 
that experienced personnel perform the procedures under sterile conditions.  
A total of 5 ml of blood (i.e. 2 teaspoons) will be collected over the course of 
the entire study. 
• Induced sputum is a procedure that will be carried out over 20 minutes.  It  is 
similar  to a nebulisation.   You will be asked  to breathe  in salt water  (saline) 
and  then  to  cough  into  a  bottle.  This  method  will  provide  a  better  quality 
sample  than  merely  coughing  into  the  bottle.  Some  patients  experience 
discomfort during  the procedure.  I will  assess your  lung  function before and 
during  the  procedure.  If  there  is  a  15%  or  greater  loss  from  baseline  the 
procedure  will  be  stopped.    The  procedure  will  also  be  stopped  if  you 
experience  severe  chest  discomfort. A  few  cases of  shortness  of  breath have 
occurred during the procedure. These complications occurred  in people with 
underlying lung pathology and that is why these patients have to be excluded 
from the study (refer to exclusion criteria). However we will be equipped with 
emergency  medication  (oxygen  masks  and  bronchodilators)  to  assist  you 
BENEFITS: 
• The potential benefit from your participation in this study is that the diagnosis 
of  TB  (which  may  have  been  missed  by  conventional  methods)  may  be 
confirmed, as a higher quality sample (i.e., induced sputum) will be used. This 
may  also  assist  in  the  diagnosis  being made  sooner  than  current  diagnostic 
tests.  Hence,  treatment  will  be  initiated  sooner  than  with  the  conventional 
methods. 
• However, you may not benefit from this study. 
• Your participation in this study will also contribute to medical knowledge that 
may help other patients. 
 
RISKS 
• Except  for  the risks associated with  the procedure (as mentioned above), no 
ther risks are involved. o
 
RIGHTS AS   PARTICIPANT IN THIS STUDY:  A
 Voluntary:  
• Your  participation  in  this  study  is  entirely  voluntary  and  you  can  decline  to 
partici ate, or stop at any time, without stating any reason.   p
Withdrawal:   
• Your withdrawal will not affect your access to other medical care.  
• I  retain  the  right  to withdraw you  from  the  study  if  it  is  considered  to be  in 
your best interest.  
REIMBURSEMENT FOR STUDY PARTICIPATION: 
• You will not be paid  to participate  in  this  study but you will  be  reimbursed 
with R100, 00 for the transport costs incurred. This will be paid to you at your 
ollow up visit.  f
 
 ETHICAL APPROVAL: 
• This  clinical  study  protocol  has  been  submitted  to  the  University  of  the 
Witwatersrand,  Human  Research  Ethics  Committee  (HREC)  and  that 
r  
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committee has g anted written approval.  
• The  study  has  been  structured  in  accordance  with  the  Declaration  of 
Helsinki  (last  updated:  October  2008),  which  deals  with  the 
recommendations  guiding  doctors  in  biomedical  research  involving  human 
participants.  A copy may be obtained from me should you wish to review it. I 
do  not  have  any  financial  or  personal  interests  that may  bias my  actions.  If 
you want any information regarding your rights as a research participant, 
or  complaints  regarding  this  research  study,  you  may  contact  Prof. 
Cleaton‐Jones,  Chairperson  of  the  University  of  the  Witwatersrand,  Human 
Research  Ethics  Committee  (HREC),  which  is  an  independent  committee 
established  to  help  protect  the  rights  of  research  participants  at  (011)  717 
301. 2
 
 
 CONFIDENTIALITY: 
• All information obtained during the course of this study, including hospital 
records, personal data and research data will be kept strictly confidential.  
Data that may be reported in scientific journals will not include any 
information that identifies you as a participant in this study. 
• The information might also be inspected by the University of the 
Witwatersrand, Human Research Ethics Committee (HREC), as well as your 
personal doctor. 
• These records will be utilised by them only in connection with carrying out 
their obligations relating to this clinical study. 
• Any information uncovered regarding your test results or state of health as a 
result of your participation in this study will be held in strict confidence.  You 
or your doctor will be informed of any finding of importance to your health but 
confidential information will not be disclosed to any third party without your 
written permission. The only exception to this rule will be cases of 
communicable diseases where a legal duty of notification of the Department of 
Health exists.  In this case, you will be informed of my intent to disclose such 
information to the authorised state agency. 
 
PARTICIPANT QUESTIONS ?: 
If you have any questions please ask and I will do my best to answer them. If you have 
additional questions in the future you can  reach  me, Dr Suvarna Buldeo on 
0833053665/011 4898432. 
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APPENDIX 3:  Informed Consent 
 
I hereby confirm that I have been informed by the study doctor, Dr S Buldeo, about 
the  a c s
acti B c
n ture,  onduct, benefit  and risks of the clinical study entitled “Diagnosis of 
ve TB using flow cytometry in HIV infected individuals in a T  endemi  setting”.  
 I  have  also  received,  read  and  understood  the  above  written  information 
(Participant Information Sheet) regarding the clinical study. 
 I am aware that the results of the study, including personal details regarding my 
sex, age, date of birth, initials and diagnosis will be anonymously processed into a 
study report. 
 I may, at any stage, without prejudice, withdraw my consent and participation in 
the study. 
 I  have  had  sufficient  opportunity  to  ask  questions  and  (of  my  own  free  will) 
declare myself prepared to participate in the study.  
ARTICIPANT: 
 
P
 
Printed Name       Signature / Mark or Thumbprint      Date 
and Time 
 
 
I,  Dr  Suvarna  Buldeo  herewith  confirm  that  the  above  participant  has  been  fully 
informed about the nature, conduct and risks of the above study. 
S
 
TUDY DOCTOR: 
Printed Name      Signature          Date 
nd Time a
 
 
TRANSLATOR  /  OTHER  PERSON  EXPLAINING  INFORMED 
ONSENT…………………(DESIGNATION): C
 
 
Printed Name        Signature        Date 
nd Time a
 
 
 
 
71 
 
WITNESS (If applicable): 
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Printed Name        Signature        Date 
and Time 
 
  
 
I hereby confirm that I have been informed by the study doctor, Dr S Buldeo that at 
the end of the study left‐over blood and/or sputum may be stored for future testing. 
This may include genetic testing related to HIV and/or TB and ethics approval will be 
sought prior to use. 
 
 
 
 
 
I 
_________________________________________________________________________
______________________ 
 
Give permission for my blood and /or induced sputum to be stored for future testing 
relating to TB and HIV research including genetic research. I understand that this 
permission for future research on my stored sample will be sought from the Wits Human 
Research Ethics Committee. 
 
 
 
PARTICIPANT: 
 
Printed Name       Signature / Mark or Thumbprint      Date 
and Time 
 
 
 
STUDY DOCTOR: _______________________________________________ 
 
 
 
TRANSLATOR:     ________________________________________________ 
 
 
 APPENDIX 4: Clinical Data Sheet  
PATIENT NAME:                                                                    Date: 
 
DOB:                                                                                         AGE: 
 
MEDICAL ILLNESSES: 
 
RESPIRATORY SYMPTOMS: 
 
RESPIRATORY SIGNS: 
 
IS EXTRA‐PULMONARY TB SUSPECTED: 
Site: 
Reason for suspicion: 
 
BCG VACCINATION: 
 
MEDICATION: 
 
CD4 count: 
 
PREVIOUS MICROSCOPY FOR TB: 
Date: _________________ Result: 
Date: _________________ Result:  
Date: _________________ Result: 
 
PREVIOUS TB: 
Duration of treatment: 
 
Productive/ non: ___________________ 
 
PLEASE NOTE WHETHER YOUR PATIENT HAS ANY OF THE FOLLOWING EXCLUSION 
CRITERIA: 
General:  Yes  No 
Smear positive TB     
Current TB therapy     
Current immunosuppressive use     
 
Suitability for Induced Sputum:     
Asthma     
COPD     
Recent life‐threatening illness     
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APPENDIX 5: Intracellular Staining Protocol for Blood and ISp 
 
Blood and sputum processing 
 
Blood Induced Sputum 
• Add 4.5 ml warm Histopaque to 15ml 
conical tube. Invert ACD tube 3x and 
add blood. 
 
• Centrifuge @ 800g for 20min with 
the brake off. 
• Split sample for microbiology if 
necessary. Add immunological 
aliquot to 15ml conical tube. 
 • To immunological aliquot add equal 
volumes of Sputolysin 
 • Rock for 20min at RT. 
• Transfer buffy coat to 15ml conical 
tube. Combine both blood tubes. 
Store serum. 
• Filter the suspension with the 100um 
strainer into 50ml conical tube. 
Empty 50ml back into 15ml conical 
tube. 
• Wash with PBS and 0.1% FBS. 
Centrifuge at 400g for 10min – brake 
on. 
• Wash with PBS and 0.1%FBS. 
Centrifuge at 400g for 10mins. 
• Decant and resuspend. • Decant supernatant and resuspend. 
• Repeat wash as above. • Add 1500ul of R10 
 • Remove 20ul and perform cell count 
and viability 
• Add 2ml R10. Perform cell count and 
viability. 
• Dilute if possible to obtain 1 million 
cells per tube. 
 
Day 1 – PBMC Stimulation 
1. Add 0.5ml cells to labelled polypropylene tubes (NB: ensure that tubes have lids & 
that proper “cloudy” tubes are used for stimulation). Keep any cells that may be left 
over – to set FSC and SSC. 
2. Add 0.25ml co-stimulation mix per tube (Reagent 1). Make up co-stim master mix 
according to number of tubes in experiment. This contains Brefeldin A. 
3. Add 0.25ml peptide stimulation mix to appropriate tubes (Reagent 2). 
4. Add 0.25ml SEB mix to SEB stimulated tubes (Reagent 3). Always add SEB last as 
prone to contaminating other tubes. Use a designated pipette. 
5. Add 0.25ml R10 to co-stimulated only tubes. 
6. Gently shake tubes to mix and incubate at 5%CO2  at 370C with cap loosened and tubes 
at an angle for 16 hrs. If not acquiring immediately after incubation the samples must 
be refrigerated at 40C. 
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Day 2 – Surface & Intracellular Staining 
1. Remove cells from incubator and record total stimulation time. 
2. Add 50μL of FastImmune EDTA to each tube and vortex for 3 sec. 
Prepare surface stain mix and ICS mix. 
3. Incubate at room temperature (18-250C) for 15min in the dark. 
4. Add 2.5ml 0.5% Wash Buffer (Reagent 4) (or BD CellWash). (NB: amount added does 
not have to be accurate). 
5. Centrifuge tubes at 300g for 5min. 
6. Decant supernatant and gently blot on paper towel for 1 second. 
7. Shake tubes to mix cells. Approximately 50μl of fluid remains. 
8. Add 150μL (or 100μL depending on surface stain mix protocol – see Experiment-
specific Worksheet) of prepared surface stain mix to each tube and mix gently 
(Reagent 5). Always work from a master-mix to maintain consistency.  
9. Cover with foil and incubate at room temperature in the dark for 20min.  
Prepare wash buffer. 
10. Add 2.5ml 0.5% Wash Buffer (or BD Cell Wash) per tube. 
11. Centrifuge at 300g for 5min. 
12. Decant supernatant without blotting. Resuspend. 
13. Add 250μL BD Cytofix/Cytoperm to each tube & gently mix.  Use neat as it is pre-
diluted. 
14. Cover with foil and incubate at room temperature in the dark for 20min. 
Permeabilisation is toxic to cells, hence the time can be shortened but not prolonged. 
Prepare comp tubes. 
15. Add 2.5ml 1X BD Perm/Wash buffer to each tube (Appendix 6). Make up wash buffer 
according to number of tubes and number of total washes - i.e. three).  
16. Centrifuge at 500g for 8min (NB: increased centrifugation following 
permeabilization). 
17. Decant supernatant without blotting & resuspend. 
18. Repeat wash steps (22 and 23). Two washes are essential to remove the 
Cytofix/Cytoperm. 
19. Decant supernatant and blot as in 13. Resuspend. 
 
From this point forward, take special care to keep samples cold and protect from light. 
 
20. Add 150ul (or 100μL depending on surface stain mix protocol – see Experiment-
specific Worksheet & Reagent 7) of prepared ICS mix and gently mix. 
21. Cover tubes with foil and incubate at 4oC for 45min.  
Run CST, 1X and comp tubes. 
22. Add 2.5ml 1X BD Perm/Wash buffer to each tube. 
23. Centrifuge at 500g for 8min. 
24. Decant supernatant and gently blot on paper towel for 1 second. Resuspend. 
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25. Add 300μl 1% paraformaldehyde “Fix” (Reagent 8) (or BD CellFix) to each tube. 
26. Store samples at 40C until acquisition. Acquire within 6hrs of sample preparation. 
 
 
 
COMPENSATION: 
 
1. Label tubes appropriately. 
2. Vortex comp beads. 
3. Add 1 drop Positive beads (Mouse Ig kappa) to each tube. 
4. Add 1 drop Negative beads (Mouse Ig kappa) to negative tube. 
5. Add corresponding Ab-PBS mix with a final volume of 50ul. 
6. Incubate in dark for 20min. 
7. Wash  with PBS: 300g for 10min. 
8. Decant. 
9. Add 200ul 1% Cell Fix. 
 
 
 
 
Reagents 
1. Co-stimulation Mix 1 
CD28 (1mg/ml) – 1μl        Make up volume to 125ul with R10.  
CD49d (1mg/ml) – 1μl            
   
2. Co stimulation mix 2 
Brefeldin A (10mg/ml) – 0.5μl  Make up volume to 125μl per reaction with R10 
 
3. Peptide stimulation Mix (PPD, ESAT6 mix concentration pending) 
Dilute peptides in R10 to give a volume of 250μl with a 10μg/ml final concentration. 
 
4. SEB Mix 
SEB (1mg/ml): Add 1μl to 249ul R10 
 
5. 0.5% Wash Buffer (Gibco – cat: 481819) 
Add 5ml Fetal Bovine Serum to 495ml Phosphate buffer saline 
 
6. Surface Stain Mix 
Add antibodies for surface staining (see reagent template worksheet) to wash buffer to make 
up to final volume of 100μl per test. CD3 is downregulated and should be added at ICS step. 
 
7. 1X BD Cytofix/Cyoperm Buffer: Catalogue 554715 
Add 1ml 10X Perm/Wash concentrate buffer to 9ml distilled water. 
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Cytofix/Cytoperm (Fix/Perm) is used neat. 
Note: It is important that the BD Perm/Wash™ Buffer be used for dilution of anti cytokine 
antibodies, rather than a standard staining buffer, in order to maintain cells in a permeabilized 
state for ICS. 
 
8. Intracellular Stain (ICS) Mix 
Add antibodies for intracellular staining (volumes determined by antibody titration) to wash 
buffer (BD wash buffer as per cytofix/cytoperm) to make up a final volume of 150μl per test. 
 
 
9. 1% Paraformaldehyde “Fix” 
Dilute 37% formalin 1:37 with PBS to give a 1% solution. 
 
 
10. R10 
Add 50ml FBS to 440ml RPMI plus 5ml antibiotics (penicillin/streptomycin/glutathione). 
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APPENDIX 6: Reagent template 
• Each patient will have eight tubes: Blood (PPD/ ESAT6/SEB and unstim).  
ISp (PPD/  ESAT6/SEB and unstim) 
• One positive control will be performed per run 
 
 
DATE:________________________ 
 
NAME HOSPITAL NUMBER OTHER DETAILS 
1. 
 
  
2. 
 
  
3. 
 
  
4. 
 
  
3. 
 
  
6. 
 
  
 
 
SURFACE STAIN MIX   
FLOUROPHORE SURFACE 
BIOMARKER 
TITRATION 
VOLUME 
NO OF 
TUBES 
TOTAL 
PerCP Cy3.5 CD4  15 ul   
APC CD27 10 ul   
WASH BUFFER  75ul   
TOTAL  100UL   
 
 
ICS MIX  
FLOUROPHORE SURFACE 
BIOMARKER 
TITRATION 
VOLUME 
NO OF 
TUBES 
TOTAL 
PE IFNγ 15 ul   
FITC CD3 15 ul   
WASH BUFFER  70 ul   
TOTAL  100ul   
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BD WASH BUFFER 
 
WASH BUFFER DH2O 
                   1ml 9ml 
 
- 2.5ml of diluted wash buffer required per tube per wash. 
- Therefore total wash buffer required = 2.5ml x 3 washes x no of tubes. 
- Eg. 2.5 x 3 x 6 tubes = 45 ml wash buffer required in total 
- Using ratio of 1:9 … 5ml WB : 45ml dH20 
 
 
PPD and ESAT6 
 
- PPD and ESAT6 are aliquoted into concentrations of 100ug/ml. 
- 10 ug/ml are required for the assay. 
- Using the equation:         C1V1 = C2V2 
                                      (100ug/ml) V1 = (10ug/ml)(1000ul) 
                                              V1 = 100ul     
       
- hence 100ul of the aliquot is required per tube for the assay. 
- PPD and ESAT6 are not added to the co-stim tube which serves as the negative 
control. 
 
 
 
 
 
CO-STIM MIX (required for all tubes) 
 
Co-stim Volume per tube No of Tubes Total 
CD28 (1mg/ml) 1ul   
CD49d (1mg/ml) 1ul   
Brefeldin A 
(10mg/ml) 
0.5ul   
R10 247.5ul   
Total 250ul   
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CELL COUNT AND VIABILITY 
 
PATIENT AVERAGE CELLS 
/SQUARE 
VIABILITY (%) RSULTS 
1.    
2.    
3.    
4.    
3.     
 6.    
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haemacytometer Counts Turk Cell Count
Cell Count 
(Viable)
Cell Count 
(non-viable)
Square #1 
Square #2 
Square #3 
Square #4 
Average # Cells / Square 
Cell Concentration (cell/ml) = (Av. # cells/square) x
(10,000) x 2 (dilution factor) x % viability 
Viable Cell Concentration (cell/ml) = (Av. # viable
cells/square) x (10,000) x 2 (dilution factor)
% Viability = (Av. # viable cells per square / Av. # 
total cells per square ) x (100)
Total Number of Viable Cells = (viable cell
concentration) x ( total volume (in ml)) 
Comments:
Reviewed By:________________     Signature:____________________________________
Date (ddmmmyy):________________ 
NOTE:  If the cell count is less than 25 or greater than 100 cells per square, the accuracy of the cell count may
be compromised.  If the total number of cells per square is greater than 100, increase the volume of the original
cell suspension to get the number of cells/square to > 25 and < 100 cells/square.  Prepare a new cell/dye 
suspension and repeat the count.  If the total number of cells is less than 25, re-pellet the PBMCs and resuspend 
in a smaller volume to get the number of cells to > 25 and < 100 cells/square. Prepare a new cell/dye 
suspension and repeat the count.  Take note of the new cell volumes.
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